• Klaria Pharma registered a prospectus for a rights issue that includes the issuance of up to 61,494,038 warrants series TO1 issued free of charge.
• The warrants will be issued as part of units in a rights issue of up to 61,494,038 units, each comprising four new shares and one warrant.
• Each warrant series TO1 can be exercised to subscribe for one new share at SEK 0.60 during set exercise windows from Nov. 22-26, 2027 through Oct. 17-31, 2029.
• If fully exercised, the warrants could raise about SEK 36.9 million before issue costs.
• Klaria plans to seek admission to trading of the warrants on Nasdaq First North Growth Market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Klaria Pharma Holding AB published the original content used to generate this news brief via Cision (Ref. ID: 20261013:BIT:2990:0) on October 13, 2026, and is solely responsible for the information contained therein.